Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Pasithea Therapeutics Corp
(NQ:
KTTA
)
4.780
+0.178 (+3.87%)
Streaming Delayed Price
Updated: 2:56 PM EDT, Aug 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Pasithea Therapeutics Corp
< Previous
1
2
3
4
5
6
7
Next >
New Drugs And Therapies Are Giving MS And ALS Sufferers New Hope
October 10, 2022
People suffering from incurable neurological diseases such as multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) hope new therapies and drugs will arrive sooner than later.
Via
Benzinga
Biotech Company Pleased With Results Of Early Testing Demonstrating Vaccine Potential For Multiple Sclerosis
October 03, 2022
By Mark Gilman, Benzinga
Via
News Direct
Biotech Company Pleased With Results Of Early Testing Demonstrating Vaccine Potential For Multiple Sclerosis
October 03, 2022
Vaccines that boost the body’s immune system against foreign proteins are different than those that are an inverse vaccine fighting an autoimmune disease.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
August 31, 2022
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
August 30, 2022
Via
Benzinga
Pasithea Therapeutics Awarded A Drug Development Research Grant
July 14, 2022
-- AUD $1 million (U.S $694,000) grant transferred as part of Alpha-5 Integrin, LLC transaction -- -- Provides approximately U.S. $694,000 of non-dilutive funding --
Via
Benzinga
EXCLUSIVE: Pasithea's Multiple Sclerosis Vaccine Candidate Shows Efficacy In Animal Studies, With Potential In Monkeypox
August 11, 2022
Pasithea Therapeutics Corp (NASDAQ: KTTA) has announced results from a preliminary preclinical proof of concept study of PAS002, its tolerizing vaccine for multiple sclerosis (MS).
Via
Benzinga
Smaller Biotechs May Pave Way For New Generation Of Therapeutics For Hard-to-Treat Neurological Disorders
August 08, 2022
An estimated 200 million Americans — more than 60% of the population — suffer from at least one neurological disorder. That includes dementia, strokes, migraines and other diseases or infections that...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
August 02, 2022
Gainers Applied DNA Sciences (NASDAQ:APDN) stock rose 90.0% to $5.32 during Tuesday's after-market session. At the close, Applied DNA Sciences's trading volume reached 28.8 million shares. This is...
Via
Benzinga
A Monoclonal Antibody Treatment For ALS Could Begin Human Trials By 2023, According To Pasithea
July 28, 2022
Pasithea Therapeutics Corp. (NASDAQ: KTTA), a biotech company looking for new treatments for psychiatric and neurological disorders, received an AU$1 million (US$694,000) gran
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
July 22, 2022
Gainers
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
July 20, 2022
Gainers NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares increased by 15.1% to $0.63 during Wednesday's after-market session. The company's market cap stands at $16.7 million.
Via
Benzinga
Pasithea's Latest Drug Candidate Could Bring New Hope To ALS Patients Without Effective Treatment Options
July 20, 2022
Amyotrophic lateral sclerosis (ALS) is a rare but painful and fatal disease that slowly shuts down all voluntary movements in the body, from walking to breathing.
Via
Benzinga
Pasithea Therapeutics Receives AUD $1 Million Research Award Following Recent Acquisition
July 18, 2022
Pasithea Therapeutics Corp. (NASDAQ: KTTA) recently announced the availability of an AUD $1 million (USD $694,000) drug development research award following the Company's acquisition of Alpha-5...
Via
Benzinga
This Biotech Company Says That It's Looking To Deliver A Breakthrough In Psychiatric Medicine — What's The Scoop?
June 27, 2022
Pasithea Therapeutics Corp. (NASDAQ: KTTA) is a biotech company with a goal of investigating novel drug treatments to provide more effective relief to the estimated 792 million people around the world...
Via
Benzinga
EXCLUSIVE: Pasithea Expands Its Core Therapeutic Pipeline With This Acquisition
June 22, 2022
Pasithea Therapeutics Corp (NASDAQ: KTTA) has acquired Alpha-5 integrin LLC, a privately-held preclinical-stage company developing a monoclonal antibody (mAbs) for amyotrophic lateral sclerosis (ALS)...
Via
Benzinga
Pasithea Biotech Reports That It's Aiming To Be At The Forefront Of The Mental Health Revolution
April 25, 2022
Image provided by Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
Via
Benzinga
Virtual Reality Technologies Are Reportedly Unlocking New Possibilities For Mental Healthcare
April 18, 2022
Image provided by Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
Via
Benzinga
Pasithea Reveals Cash Position Of $52.9 Million In Latest Earnings Report, To Expand Pipeline And Fund Operations Well Into 2024
April 01, 2022
Image sourced from Pixabay
Via
Benzinga
This Ketamine-Assisted Therapy Company Is Developing New Ways To Treat Alcohol Addiction
March 24, 2022
Picture credit: Martin Sanchez on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
May 17, 2022
On Tuesday, 123 stocks made new 52-week lows.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
March 15, 2022
Gainers Incannex Healthcare (NASDAQ:IXHL) stock moved upwards by 92.3% to $44.04 during Tuesday's pre-market session. The market value of their outstanding shares is...
Via
Benzinga
Pasithea Partners With Glimpse Group To Co-Develop VR Environments For Patients With Psychiatric Disorders
March 10, 2022
Photo by Maxim Hopman on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice....
Via
Benzinga
EXCLUSIVE: Glimpse-Pasithea To Co-Develop VR Environments For Patients With Psychiatric Disorders
March 08, 2022
Pasithea Therapeutics Corp (NASDAQ: KTTA) has partnered with Glimpse Group Inc (NASDAQ: VRAR), a Virtual Reality and Augmented Reality (VR / AR) platform company, and its...
Via
Benzinga
This Company Reports Using Ketamine To Treat Mental Health Disorders
March 07, 2022
Photo by Sydney Sims on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice....
Via
Benzinga
Pasithea To Open 3 New Clinics In The U.K. For Patients with Mental Health Issues, Each Clinic Expected To Add ~$5 Million In Annual Revenue
February 25, 2022
Image by Christina on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Pasithea...
Via
Benzinga
Pasithea Therapeutics Announces Plans To Open Three New Clinics In The UK By Mid-2022
February 24, 2022
-- Each clinic expected to contribute an estimated USD$5 million (£4 million) annually in revenue -- -- New London locations will provide pharmacy services, ketamine therapy...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
February 03, 2022
Gainers Cidara Therapeutics (NASDAQ:CDTX)...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
February 03, 2022
Gainers SOC Telemed (NASDAQ:TLMD) shares increased by 338.2% to $2.82 during Thursday's pre-market session. The market value of their outstanding shares is at $284.5...
Via
Benzinga
EXCLUSIVE: Pasithea Therapeutics Starts New Multiple Sclerosis Vaccine Development Program
February 03, 2022
Pasithea Therapeutics Corp (NASDAQ: KTTA) has announced a new chemical entity (NCE) development program and named Massachusetts-based Hooke Laboratories as its research partner.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.